Welcome to LookChem.com Sign In|Join Free
  • or
3-Amino-N-benzylpropanamide hydrochloride is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

202819-53-2

Post Buying Request

202819-53-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

202819-53-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 202819-53-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,8,1 and 9 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 202819-53:
(8*2)+(7*0)+(6*2)+(5*8)+(4*1)+(3*9)+(2*5)+(1*3)=112
112 % 10 = 2
So 202819-53-2 is a valid CAS Registry Number.

202819-53-2Relevant academic research and scientific papers

Sulfur incorporation generally improves Ricin inhibition in pterin-appended glycine-phenylalanine dipeptide mimics

Wiget, Paul A.,Manzano, Lawrence A.,Pruet, Jeff M.,Gao, Grace,Saito, Ryota,Monzingo, Arthur F.,Jasheway, Karl R.,Robertus, Jon D.,Anslyn, Eric V.

, p. 6799 - 6804 (2014/01/06)

Several 7-aminoamido-pterins were synthesized to evaluate the electronic and biochemical subtleties observed in the 'linker space' when N-{N-(pterin-7-yl)carbonylglycyl}-l-phenylalanine 1 was bound to the active site of RTA. The gylcine-phenylalanine dipeptide analogs included both amides and thioamides. Decarboxy gly-phe analog 2 showed a 6.4-fold decrease in potency (IC50 = 128 μM), yet the analogous thioamide 7 recovered the lost activity and performed similarly to the parent inhibitor (IC50 = 29 μM). Thiourea 12 exhibited an IC50 nearly six times lower than the oxo analog 13. All inhibitors showed the pterin head-group firmly bound in their X-ray structures yet the pendants were not fully resolved suggesting that all pendants are not firmly bound in the RTA linker space. Calculated log P values do not correlate to the increase in bioactivity suggesting other factors dominate.

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

-

, (2009/10/31)

The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 202819-53-2